Context Therapeutics (CNTX) Income from Continuing Operations (2020 - 2026)

Context Therapeutics has disclosed Income from Continuing Operations across 7 years of filings, most recently posting 8823660.0 for Q1 2026.

• Income from Continuing Operations for Q1 2026 came in at 8823660.0, down 93.05% year-over-year; the trailing twelve-month figure through Mar 2026 was 40577120.0 (down 46.9% YoY), and the FY2025 annual result was 36324086.0, down 35.92% from the prior year.
• Income from Continuing Operations came in at 8823660.0 for Q1 2026 at Context Therapeutics, up from 13122162.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 2248399.0 in Q2 2024 to a low of 17457741.0 in Q3 2024.
• The 5-year median for Income from Continuing Operations is 5292368.0 (2023), against an average of 6607367.12.
• Across the five-year window, Income from Continuing Operations surged 57.52% in 2024 and plunged 293.82% in 2025, its largest moves.
• Context Therapeutics' Income from Continuing Operations stood at 3882343.0 in 2022, then plunged by 78.58% to 6933205.0 in 2023, then surged by 51.73% to 3346386.0 in 2024, then sank by 292.13% to 13122162.0 in 2025, then jumped by 32.76% to 8823660.0 in 2026.
• The last three Income from Continuing Operations figures came in at 8823660.0 (Q1 2026), 13122162.0 (Q4 2025), and 9776708.0 (Q3 2025), per Business Quant data.